Abvc Biopharma Stock Performance
| ABVC Stock | USD 2.19 0.06 2.82% |
The firm shows a Beta (market volatility) of 1.79, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ABVC Biopharma will likely underperform. At this point, ABVC Biopharma has a negative expected return of -0.49%. Please make sure to confirm ABVC Biopharma's accumulation distribution, and the relationship between the potential upside and day median price , to decide if ABVC Biopharma performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ABVC Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 2.82 | Five Day Return (9.88) | Ten Year Return (99.85) | All Time Return (100.00) |
Last Split Factor 1:10 | Dividend Date 2019-05-08 | Last Split Date 2023-07-25 |
1 | ABVC BioPharma Has Received a Cumulative Total of US566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus Production | 10/08/2025 |
2 | Acquisition by Smith J.b. of 40000 shares of ABVC Biopharma at 0.75 subject to Rule 16b-3 | 10/15/2025 |
3 | Real time pattern detection on ABVC BioPharma Inc. stock - Market Activity Summary Fast ExitEntry Strategy Plans - newser.com | 10/28/2025 |
4 | ABVC BioPharma Receives Additional US100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US695,950 | 10/31/2025 |
5 | ABVC BioPharma Reports 230 percent YoY Licensing Revenue Growth and 181 percent Asset Expansion in Q3 2025 | 11/03/2025 |
6 | Can ABVC BioPharma Inc. stock double in next 5 years - 2025 Trade Ideas Free Safe Capital Growth Stock Tips - fcp.pa.gov.br | 11/06/2025 |
7 | Will ABVC BioPharma Inc. stock sustain high P E ratios - 2025 Price Action Summary Risk Controlled Daily Trade Plans - newser.com | 11/11/2025 |
8 | How ABVC BioPharma Inc. stock benefits from strong dollar - IPO Watch Target Return Focused Stock Picks - newser.com | 11/14/2025 |
9 | Is ABVC BioPharma Inc. stock cheap compared to fundamentals - 2025 Institutional Moves Consistent Profit Trade Alerts - newser.com | 11/19/2025 |
10 | Acquisition by Smith J.b. of 500000 shares of ABVC Biopharma at 0.9 subject to Rule 16b-3 | 11/20/2025 |
11 | Disposition of tradable shares by King Chi-hsin Richard of ABVC Biopharma subject to Rule 16b-3 | 11/25/2025 |
12 | Acquisition by Smith J.b. of 11500 shares of ABVC Biopharma at 0.75 subject to Rule 16b-3 | 12/03/2025 |
13 | Acquisition by Ramsey Sally Judith of tradable shares of ABVC Biopharma at 80000.0 subject to Rule 16b-3 | 12/12/2025 |
14 | Can ABVC BioPharma Inc. stock hit analyst price targets - July 2025 Technicals Low Risk Growth Stock Ideas - | 12/19/2025 |
ABVC Biopharma Relative Risk vs. Return Landscape
If you would invest 313.00 in ABVC Biopharma on October 6, 2025 and sell it today you would lose (94.00) from holding ABVC Biopharma or give up 30.03% of portfolio value over 90 days. ABVC Biopharma is currently does not generate positive expected returns and assumes 3.8324% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than ABVC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ABVC Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ABVC Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ABVC Biopharma, and traders can use it to determine the average amount a ABVC Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1283
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABVC |
Based on monthly moving average ABVC Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ABVC Biopharma by adding ABVC Biopharma to a well-diversified portfolio.
ABVC Biopharma Fundamentals Growth
ABVC Stock prices reflect investors' perceptions of the future prospects and financial health of ABVC Biopharma, and ABVC Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ABVC Stock performance.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (1.47) % | ||||
| Current Valuation | 54.35 M | ||||
| Shares Outstanding | 24.3 M | ||||
| Price To Book | 4.41 X | ||||
| Price To Sales | 66.70 X | ||||
| Revenue | 509.59 K | ||||
| Gross Profit | 797.92 K | ||||
| EBITDA | (4.34 M) | ||||
| Net Income | (5.26 M) | ||||
| Cash And Equivalents | 2.99 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 3.2 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.51 X | ||||
| Cash Flow From Operations | (1.81 M) | ||||
| Earnings Per Share | (0.28) X | ||||
| Market Capitalization | 53.22 M | ||||
| Total Asset | 7.54 M | ||||
| Retained Earnings | (68.95 M) | ||||
| Working Capital | (4.38 M) | ||||
About ABVC Biopharma Performance
By analyzing ABVC Biopharma's fundamental ratios, stakeholders can gain valuable insights into ABVC Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ABVC Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ABVC Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.1 K | 2.3 K | |
| Return On Tangible Assets | (0.75) | (0.79) | |
| Return On Capital Employed | (5.51) | (5.78) | |
| Return On Assets | (0.75) | (0.79) | |
| Return On Equity | (3.60) | (3.42) |
Things to note about ABVC Biopharma performance evaluation
Checking the ongoing alerts about ABVC Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ABVC Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ABVC Biopharma generated a negative expected return over the last 90 days | |
| ABVC Biopharma has high historical volatility and very poor performance | |
| ABVC Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 509.59 K. Net Loss for the year was (5.26 M) with profit before overhead, payroll, taxes, and interest of 797.92 K. | |
| ABVC Biopharma currently holds about 2.99 M in cash with (1.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| ABVC Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Can ABVC BioPharma Inc. stock hit analyst price targets - July 2025 Technicals Low Risk Growth Stock Ideas - |
- Analyzing ABVC Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ABVC Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining ABVC Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ABVC Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ABVC Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ABVC Biopharma's stock. These opinions can provide insight into ABVC Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ABVC Stock analysis
When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |